NASDAQ:KMDA

Kamada Stock Forecast, Price & News

$5.67
-0.11 (-1.90 %)
(As of 06/18/2021 10:29 AM ET)
Add
Compare
Today's Range
$5.66
$5.69
50-Day Range
$5.67
$6.33
52-Week Range
$5.55
$13.33
Volume423 shs
Average Volume148,136 shs
Market Capitalization$252.43 million
P/E Ratio17.18
Dividend YieldN/A
Beta1.02
30 days | 90 days | 365 days | Advanced Chart
Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.


Kamada logo

About Kamada

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; AeroBika, an OPEP device; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.39 out of 5 stars

Medical Sector

742nd out of 2,100 stocks

Pharmaceutical Preparations Industry

367th out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Kamada (NASDAQ:KMDA) Frequently Asked Questions

Is Kamada a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kamada stock.
View analyst ratings for Kamada
or view top-rated stocks.

What stocks does MarketBeat like better than Kamada?

Wall Street analysts have given Kamada a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kamada wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Kamada's next earnings date?

Kamada is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Kamada
.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) posted its earnings results on Wednesday, May, 12th. The biotechnology company reported $0.06 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.09 by $0.03. The biotechnology company had revenue of $24.90 million for the quarter, compared to the consensus estimate of $26.45 million. Kamada had a trailing twelve-month return on equity of 8.27% and a net margin of 11.70%.
View Kamada's earnings history
.

How has Kamada's stock price been impacted by Coronavirus?

Kamada's stock was trading at $5.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KMDA shares have increased by 10.1% and is now trading at $5.67.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for KMDA?

2 brokerages have issued 1-year price targets for Kamada's stock. Their forecasts range from $11.00 to $11.00. On average, they expect Kamada's stock price to reach $11.00 in the next year. This suggests a possible upside of 94.0% from the stock's current price.
View analysts' price targets for Kamada
or view top-rated stocks among Wall Street analysts.

Who are Kamada's key executives?

Kamada's management team includes the following people:
  • Mr. Amir London, Chief Exec. Officer (Age 52, Pay $628k)
  • Mr. Chaime Orlev, Chief Financial Officer (Age 51, Pay $332k)
  • Mr. Eran Nir, VP of Operations (Age 48, Pay $328k)
  • Dr. Michal Ayalon-Soffer, VP of R&D and IP (Age 54, Pay $283k)
  • Ms. Yifat Philip Esq., VP of Legal, Gen. Counsel & Corp. Sec. (Age 44)
  • Ms. Hanni Neheman, VP of Marketing & Sales (Age 51)
  • Ms. Ariella Raban, VP of HR (Age 45)

Who are some of Kamada's key competitors?

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Who are Kamada's major shareholders?

Kamada's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.73%), Acadian Asset Management LLC (1.95%), ARK Investment Management LLC (1.95%), BlackRock Inc. (0.88%), Altshuler Shaham Ltd (0.61%) and Morgan Stanley (0.42%).

Which major investors are selling Kamada stock?

KMDA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Noked Israel Ltd, Renaissance Technologies LLC, Acadian Asset Management LLC, Meitav Dash Investments Ltd., Dimensional Fund Advisors LP, and BlackRock Inc..

Which major investors are buying Kamada stock?

KMDA stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Altshuler Shaham Ltd, JPMorgan Chase & Co., Jane Street Group LLC, Calton & Associates Inc., and Goldman Sachs Group Inc..

How do I buy shares of Kamada?

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $5.67.

How much money does Kamada make?

Kamada has a market capitalization of $252.43 million and generates $133.25 million in revenue each year. The biotechnology company earns $17.14 million in net income (profit) each year or $0.38 on an earnings per share basis.

How many employees does Kamada have?

Kamada employs 408 workers across the globe.

What is Kamada's official website?

The official website for Kamada is www.kamada.com.

Where are Kamada's headquarters?

Kamada is headquartered at 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]


This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.